Matches in Nanopublications for { ?s ?p "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP842373.RAshmDYkxgOATdI_yzrw3Bm_4u1T6Pt677Zpnx6uJMzJc130_assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP842373.RAshmDYkxgOATdI_yzrw3Bm_4u1T6Pt677Zpnx6uJMzJc130_provenance.
- assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP665112.RADruK5RT1yCVL46KqhhjH14f0gFxszl77zXE4C8kj8HA130_assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP665112.RADruK5RT1yCVL46KqhhjH14f0gFxszl77zXE4C8kj8HA130_provenance.
- NP848913.RATQ2qihdMJyY0XBZ6AKXv_rac6VeDO7W8VwvvE1N9ujM130_assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848913.RATQ2qihdMJyY0XBZ6AKXv_rac6VeDO7W8VwvvE1N9ujM130_provenance.
- NP848914.RATcGKMJ-1x-fg4Hdqu_g9ByyclnOQEIU-edpkYsPaRz0130_assertion description "[Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848914.RATcGKMJ-1x-fg4Hdqu_g9ByyclnOQEIU-edpkYsPaRz0130_provenance.